A critical role for choline kinase-α in the aggressiveness of bladder carcinomas

Oncogene

Volumn 28, Issue 26, 2009, Pages 2425-2435

  Hernando, E ^a,f   Sarmentero Estrada, J ^b   Koppie, T ^a   Belda Iniesta, C ^c   Ramirez De Molina V ^b,d   Cejas, P ^c   Ozu, C ^a   Le, C ^a   Sanchez J J ^e   Gonzalez Baron M ^c   Koutcher, J ^a   Cordon Cardo C ^a,g   Bochner, B H ^a   Lacal, J C ^b,c   De Molina, A Ramírez ^b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c CSIC   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g College of Physicians ^*  (United States)

Author keywords

Bladder cancer; Choline kinase; Therapeutic target; Tumor promoter

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLINE KINASE ALPHA; MN 58 B; ONCOPROTEIN; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; CHOLINE KINASE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM INVASIVENESS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

MURINAE; MUS;

EID: 67650064783     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.91     Document Type: Article

References (34)

1. Al-Saffar NM, Troy H, Ramirezde Molina A, Jackson LE, Madhu B, Griffiths JR et al. (2006). Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res 66: 427-434.
2. Aoyama C, Liao H, Ishidate K. (2004). Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 43: 266-281.
3. Banez-Coronel M, Ramirez de Molina A, Rodriguez-GonzalezA, Sarmentero J, Ramos MA, Garcia-Cabezas MA et al. (2008). Choline kinase alpha depletion selectively kills tumoral cells. Curr Cancer Drug Targets 8: 709-719.
4. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytono- wiczE, Hu SX et al. (1997). Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57: 1217-1221.
5. Chin J, Kadhim S, Garcia B, Kim YS, Karlik S. (1991). Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants. J Urol 145: 1297-1301.
6. Gallego-Ortega D, RamirezDe Molina A, GutierrezR, Ramos MA, Sarmentero J, Cejas P et al. (2006). Generation and characterization of monoclonal antibodies against choline kinase alpha and their potential use as diagnostic tools in cancer. Int J Oncol 29: 335-340.
7. Gallego-Ortega D, Ramirezde Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J et al. (2009). Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: potential implications in cancer onset and treatment (submitted).
8. Garraway LA, Sellers WR. (2006). Lineage dependency and lineage- survival oncogenes in human cancer. Nat Rev Cancer 6: 593-602.
9. Glunde K, Bhujwalla ZM. (2007). Choline kinase alpha in cancer prognosis and treatment. Lancet Oncol 8: 855-857.
10. Glunde K, Raman V, Mori N, Bhujwalla ZM. (2005). RNA interference- mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res 65: 11034-11043.
11. Hernandez-Alcoceba R, Fernandez F, Lacal JC. (1999). In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res 59: 3112-3118.
12. Hernandez-Alcoceba R, Saniger L, Campos J, Nunez MC, Khaless F, Gallo MA et al. (1997). Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 15: 2289-2301.
13. Hernando E, Orlow I, Liberal V, Nohales G, Benezra R, Cordon- Cardo C. (2001). Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. Int J Cancer 95: 223-227.
14. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. (2007). Cancerstatistics, 2007. CA Cancer J Clin 57: 43-66.
15. Jonkers J, Berns A. (2004). Oncogene addiction: sometimes a temporary slavery. Cancer Cell 6: 535-538.
16. Kikuchi E, MenendezS, Ohori M, Cordon-Cardo C, Kasahara N,Bochner BH. (2004). Inhibition oforthotopic human bladder tumorgrowth by lentiviral gene transfer of endostatin. Clin Cancer Res 10: 1835-1842.
17. Kikuchi E, Xu S, Ohori M, Matei C, Lupu M, MenendezS et al . (2003). Detection and quantitative analysis of early stage orthotopic murine bladder tumor using in vivo magnetic resonance imaging. J Urol 170: 1375-1378.
18. Lacal JC. (2001). Choline kinase: a novel target for antitumor drugs.IDrugs 4: 419-426.
19. Lu ML, Wikman F, Orntoft TF, CharytonowiczE, Rabbani F, Zhang Z et al. (2002). Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 8: 171-179.
20. Mullerad M, Bochner BH, Adusumilli PS, Bhargava A, Kikuchi E, Hui-Ni C et al . (2005). Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. J Urol 174: 741-746.
21. Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Suda Y, Sekine T et al . (1999). Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res 90: 419-424.
22. Oliveira PA, Colaco A, De la CruzPL, Lopes C. (2006). Experimental bladder carcinogenesis-rodent models. Exp Oncol 28: 2-11.
23. Quek ML, Stein JP, Nichols PW, Cai J, Miranda G, Groshen S et al . (2005). Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 174: 103-106.
24. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodriguez- Gonzalez A, Olmeda D, Megias D et al. (2004). Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression.Cancer Res 64: 6732-6739.
25. Ramirezde Molina A, Gallego-Ortega D, Sarmentero J, Banez- Coronel M, Martin-Cantalejo Y, Lacal JC. (2005). Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res 65: 5647-5653.
26. Ramirezde Molina A, Penalva V, Lucas L, Lacal JC. (2002a). Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3 K. Oncogene 21: 937-946.
27. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez- Pineiro L, SanchezJ, Bonilla F et al. (2002b). Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 296: 580-583.
28. Ramirezde Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirezde Molina V, Cejas P et al. (2007). Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 8: 889-897.
29. Rodriguez-Gonzalez A, Ramirez de Molina A, Banez-Coronel M, Megias D, Lacal JC. (2005). Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int J Oncol 26: 999-1008.
30. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Lacal JC. (2004). Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene 23: 8247-8259.
31. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Ramos MA, del Carmen NunezM, Campos J et al. (2003). Inhibition of choline kinase as a specific cytotoxic strategy in oncogene- transformed cells. Oncogene 22: 8803-8812.
32. Sanderson KM, Cai J, Miranda G, Skinner DG, Stein JP. (2007).Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069patients with 10-year followup. J Urol 177: 2088-2094.
33. Weinstein IB, Joe AK. (2006). Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448-457.
34. Wu XR. (2005). Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5: 713-725.